<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240905041339&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240905041339&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 05 Sep 2024 08:13:40 +0000</lastbuilddate>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Reply: Significance of B-type Natriuretic Peptide Level in Patients With Small Left Ventricle</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39232640/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240905041339&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 10;84(11):e89. doi: 10.1016/j.jacc.2024.06.030.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39232640/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240905041339&v=2.18.0.post9+e462414">39232640</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.030>10.1016/j.jacc.2024.06.030</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39232640</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Mingxiao Li</dc:creator>
<dc:creator>Liu He</dc:creator>
<dc:creator>Lan Ren</dc:creator>
<dc:creator>Caihua Sang</dc:creator>
<dc:creator>Changsheng Ma</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Significance of B-type Natriuretic Peptide Level in Patients With Small Left Ventricle</dc:title>
<dc:identifier>pmid:39232640</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.030</dc:identifier>
</item>
<item>
<title>Significance of B-Type Natriuretic Peptide Level in Patients With Small Left Ventricle</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39232639/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240905041339&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 10;84(11):e87. doi: 10.1016/j.jacc.2024.05.071.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39232639/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240905041339&v=2.18.0.post9+e462414">39232639</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.071>10.1016/j.jacc.2024.05.071</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39232639</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Tomoaki Murakami</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Significance of B-Type Natriuretic Peptide Level in Patients With Small Left Ventricle</dc:title>
<dc:identifier>pmid:39232639</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.071</dc:identifier>
</item>
<item>
<title>Reply: Potential for Misapplication of a Uniform vs Sex-Specific High-Sensitivity Cardiac Troponin Threshold</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39232638/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240905041339&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 10;84(11):e85-e86. doi: 10.1016/j.jacc.2024.06.031.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39232638/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240905041339&v=2.18.0.post9+e462414">39232638</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.031>10.1016/j.jacc.2024.06.031</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39232638</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Ziwen Li</dc:creator>
<dc:creator>Ryan Wereski</dc:creator>
<dc:creator>Nicholas L Mills</dc:creator>
<dc:creator>Dorien M Kimenai</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Potential for Misapplication of a Uniform vs Sex-Specific High-Sensitivity Cardiac Troponin Threshold</dc:title>
<dc:identifier>pmid:39232638</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.031</dc:identifier>
</item>
<item>
<title>Potential for Misapplication of a Uniform vs Sex-Specific High-Sensitivity Cardiac Troponin Threshold</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39232637/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240905041339&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 10;84(11):e83-e84. doi: 10.1016/j.jacc.2024.04.071.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39232637/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240905041339&v=2.18.0.post9+e462414">39232637</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.071>10.1016/j.jacc.2024.04.071</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39232637</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Amy G Huebschmann</dc:creator>
<dc:creator>Nanette K Wenger</dc:creator>
<dc:creator>C Noel Bairey Merz</dc:creator>
<dc:creator>Allan S Jaffe</dc:creator>
<dc:creator>Larry A Allen</dc:creator>
<dc:creator>Stacy A Trent</dc:creator>
<dc:creator>Judith G Regensteiner</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Potential for Misapplication of a Uniform vs Sex-Specific High-Sensitivity Cardiac Troponin Threshold</dc:title>
<dc:identifier>pmid:39232637</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.071</dc:identifier>
</item>
<item>
<title>Reply: The Association of Bradycardic Event Risk With Antiarrhythmic Drugs for Atrial Fibrillation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39232636/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240905041339&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 10;84(11):e81. doi: 10.1016/j.jacc.2024.06.032.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39232636/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240905041339&v=2.18.0.post9+e462414">39232636</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.032>10.1016/j.jacc.2024.06.032</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39232636</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Yun Gi Kim</dc:creator>
<dc:creator>Hyoung Seok Lee</dc:creator>
<dc:creator>Hoseob Kim</dc:creator>
<dc:creator>Jong-Il Choi</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: The Association of Bradycardic Event Risk With Antiarrhythmic Drugs for Atrial Fibrillation</dc:title>
<dc:identifier>pmid:39232636</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.032</dc:identifier>
</item>
<item>
<title>The Association of Bradycardic Event Risk With Antiarrhythmic Drugs for Atrial Fibrillation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39232635/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240905041339&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 10;84(11):e79. doi: 10.1016/j.jacc.2024.03.434.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39232635/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240905041339&v=2.18.0.post9+e462414">39232635</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.434>10.1016/j.jacc.2024.03.434</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39232635</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>James A Reiffel</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Association of Bradycardic Event Risk With Antiarrhythmic Drugs for Atrial Fibrillation</dc:title>
<dc:identifier>pmid:39232635</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.434</dc:identifier>
</item>
<item>
<title>Triglyceride Levels, Alirocumab Treatment, and Cardiovascular Outcomes After an Acute Coronary Syndrome</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39232634/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240905041339&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Among patients with recent ACS on optimized statin therapy, baseline triglycerides was associated with cardiovascular risk. However, the reduction in triglycerides with alirocumab did not contribute to its clinical benefit. (ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab; NCT01663402).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 10;84(11):994-1006. doi: 10.1016/j.jacc.2024.06.035.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: It is unknown whether clinical benefit of proprotein convertase subtilisin/kexin type 9 inhibitors is associated with baseline or on-treatment triglyceride concentrations.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to examine relations between triglyceride levels and the effect of alirocumab vs placebo on cardiovascular outcomes using prespecified and post hoc analyses of the ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patients with recent acute coronary syndrome (ACS) (n = 18,924) and elevated atherogenic lipoproteins despite optimized statin therapy were randomized to alirocumab 75 to 150 mg or matching placebo every 2 weeks subcutaneously. Major adverse cardiovascular events (MACE) were examined in relation to continuous or dichotomous triglyceride concentrations.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Median baseline triglyceride concentration was 129 mg/dL. In both treatment groups, a 10-mg/dL higher baseline concentration was associated with an adjusted MACE HR of 1.008 (95% CI: 1.003-1.013; P &lt; 0.005). Baseline triglycerides ≥150 vs &lt;150 mg/dL were associated with a HR of 1.184 (95% CI: 1.080-1.297; P &lt; 0.005). Versus placebo, alirocumab reduced low-density lipoprotein cholesterol from baseline (average, 54.7%) and reduced MACE (HR: 0.85; 95% CI: 0.78-0.93). At month 4, triglyceride levels were reduced from baseline by median 17.7 mg/dL (P &lt; 0.001) and 0.9 mg/dL (P = NS) with alirocumab and placebo, respectively. A 10-mg/dL decline from baseline in triglycerides was associated with lower subsequent risk of MACE with placebo (HR: 0.988; 95% CI: 0.982-0.995; P &lt; 0.005) but not with alirocumab (HR: 0.999; 95% CI: 0.987-1.010; P = 0.82).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Among patients with recent ACS on optimized statin therapy, baseline triglycerides was associated with cardiovascular risk. However, the reduction in triglycerides with alirocumab did not contribute to its clinical benefit. (ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab; NCT01663402).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39232634/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240905041339&v=2.18.0.post9+e462414">39232634</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.035>10.1016/j.jacc.2024.06.035</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39232634</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Doron Zahger</dc:creator>
<dc:creator>Gregory G Schwartz</dc:creator>
<dc:creator>Weiming Du</dc:creator>
<dc:creator>Michael Szarek</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:creator>Vera A Bittner</dc:creator>
<dc:creator>Andrzej J Budaj</dc:creator>
<dc:creator>Rafael Diaz</dc:creator>
<dc:creator>Shaun G Goodman</dc:creator>
<dc:creator>J Wouter Jukema</dc:creator>
<dc:creator>Robert G Kiss</dc:creator>
<dc:creator>Robert A Harrington</dc:creator>
<dc:creator>Patrick M Moriarty</dc:creator>
<dc:creator>Michel Scemama</dc:creator>
<dc:creator>Garen Manvelian</dc:creator>
<dc:creator>Robert Pordy</dc:creator>
<dc:creator>Harvey D White</dc:creator>
<dc:creator>Andreas M Zeiher</dc:creator>
<dc:creator>Sergio Fazio</dc:creator>
<dc:creator>Gregory P Geba</dc:creator>
<dc:creator>Ph Gabriel Steg</dc:creator>
<dc:creator>ODYSSEY OUTCOMES Investigators</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Triglyceride Levels, Alirocumab Treatment, and Cardiovascular Outcomes After an Acute Coronary Syndrome</dc:title>
<dc:identifier>pmid:39232634</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.035</dc:identifier>
</item>
<item>
<title>Rethinking Cholesterol Screening and Management in Young Adults: From Lost Opportunity to Prevention Win</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39232633/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240905041339&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 10;84(11):974-977. doi: 10.1016/j.jacc.2024.06.029.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39232633/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240905041339&v=2.18.0.post9+e462414">39232633</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.029>10.1016/j.jacc.2024.06.029</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39232633</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Yiyi Zhang</dc:creator>
<dc:creator>Mark J Pletcher</dc:creator>
<dc:creator>Andrew E Moran</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Rethinking Cholesterol Screening and Management in Young Adults: From Lost Opportunity to Prevention Win</dc:title>
<dc:identifier>pmid:39232633</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.029</dc:identifier>
</item>
<item>
<title>Prediction of Cumulative Exposure to Atherogenic Lipids During Early Adulthood</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39232632/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240905041339&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Single measures of non-HDL-C and LDL-C obtained between ages 18 and 30 years are highly predictive of cumulative exposure before age 40 years, which in turn strongly predicts later-life ASCVD events.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 10;84(11):961-973. doi: 10.1016/j.jacc.2024.05.070.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The ability of a 1-time measurement of non-high-density lipoprotein cholesterol (non-HDL-C) or low-density lipoprotein cholesterol (LDL-C) to predict the cumulative exposure to these lipids during early adulthood (age 18-40 years) and the associated atherosclerotic cardiovascular disease (ASCVD) risk after age 40 years is not clear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The objectives of this study were to evaluate whether a 1-time measurement of non-HDL-C or LDL-C in a young adult can predict cumulative exposure to these lipids during early adulthood, and to quantify the association between cumulative exposure to non-HDL-C or LDL-C during early adulthood and the risk of ASCVD after age 40 years.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We included CARDIA (Coronary Artery Risk Development in Young Adults Study) participants who were free of cardiovascular disease before age 40 years, were not taking lipid-lowering medications, and had ≥3 measurements of LDL-C and non-HDL-C before age 40 years. First, we assessed the ability of a 1-time measurement of LDL-C or non-HDL-C obtained between age 18 and 30 years to predict the quartile of cumulative lipid exposure from ages 18 to 40 years. Second, we assessed the associations between quartiles of cumulative lipid exposure from ages 18 to 40 years with ASCVD events (fatal and nonfatal myocardial infarction and stroke) after age 40 years.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 4,104 CARDIA participants who had multiple lipid measurements before and after age 30 years, 3,995 participants met our inclusion criteria and were in the final analysis set. A 1-time measure of non-HDL-C and LDL-C had excellent discrimination for predicting membership in the top or bottom quartiles of cumulative exposure (AUC: 0.93 for the 4 models). The absolute values of non-HDL-C and LDL-C that predicted membership in the top quartiles with the highest simultaneous sensitivity and specificity (highest Youden's Index) were >;135 mg/dL for non-HDL-C and >;118 mg/dL for LDL-C; the values that predicted membership in the bottom quartiles were &lt;107 mg/dL for non-HDL-C and &lt;96 mg/dL for LDL-C. Individuals in the top quartile of non-HDL-C and LDL-C exposure had demographic-adjusted HRs of 4.6 (95% CI: 2.84-7.29) and 4.0 (95% CI: 2.50-6.33) for ASCVD events after age 40 years, respectively, when compared with each bottom quartile.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Single measures of non-HDL-C and LDL-C obtained between ages 18 and 30 years are highly predictive of cumulative exposure before age 40 years, which in turn strongly predicts later-life ASCVD events.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39232632/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240905041339&v=2.18.0.post9+e462414">39232632</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.070>10.1016/j.jacc.2024.05.070</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39232632</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>John T Wilkins</dc:creator>
<dc:creator>Hongyan Ning</dc:creator>
<dc:creator>Norrina B Allen</dc:creator>
<dc:creator>Alexander Zheutlin</dc:creator>
<dc:creator>Nilay S Shah</dc:creator>
<dc:creator>Matthew J Feinstein</dc:creator>
<dc:creator>Amanda M Perak</dc:creator>
<dc:creator>Sadiya S Khan</dc:creator>
<dc:creator>Ankeet S Bhatt</dc:creator>
<dc:creator>Ravi Shah</dc:creator>
<dc:creator>Venkatesh Murthy</dc:creator>
<dc:creator>Allan Sniderman</dc:creator>
<dc:creator>Donald M Lloyd-Jones</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Prediction of Cumulative Exposure to Atherogenic Lipids During Early Adulthood</dc:title>
<dc:identifier>pmid:39232632</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.070</dc:identifier>
</item>
<item>
<title>Mavacamten in Obstructive Hypertrophic Cardiomyopathy Patients Referred for Septal Reduction: Health Status Analysis Through Week 56 in VALOR-HCM Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39232631/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240905041339&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 10;84(11):1041-1045. doi: 10.1016/j.jacc.2024.06.025.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39232631/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240905041339&v=2.18.0.post9+e462414">39232631</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.025>10.1016/j.jacc.2024.06.025</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39232631</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Milind Y Desai</dc:creator>
<dc:creator>Anjali Owens</dc:creator>
<dc:creator>Kathy Wolski</dc:creator>
<dc:creator>Jeffrey B Geske</dc:creator>
<dc:creator>Sara Saberi</dc:creator>
<dc:creator>Andrew Wang</dc:creator>
<dc:creator>Mark Sherrid</dc:creator>
<dc:creator>Paul C Cremer</dc:creator>
<dc:creator>Neal K Lakdawala</dc:creator>
<dc:creator>Albree Tower-Rader</dc:creator>
<dc:creator>David Fermin</dc:creator>
<dc:creator>Srihari S Naidu</dc:creator>
<dc:creator>Nicholas G Smedira</dc:creator>
<dc:creator>Hartzell Schaff</dc:creator>
<dc:creator>Ellen McErlean</dc:creator>
<dc:creator>Christina Sewell</dc:creator>
<dc:creator>Yue Zhong</dc:creator>
<dc:creator>Kathleen W Wyrwich</dc:creator>
<dc:creator>Kathy L Lampl</dc:creator>
<dc:creator>Amy J Sehnert</dc:creator>
<dc:creator>Steven E Nissen</dc:creator>
<dc:creator>John A Spertus</dc:creator>
<dc:creator>VALOR-HCM Investigators</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Mavacamten in Obstructive Hypertrophic Cardiomyopathy Patients Referred for Septal Reduction: Health Status Analysis Through Week 56 in VALOR-HCM Trial</dc:title>
<dc:identifier>pmid:39232631</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.025</dc:identifier>
</item>
<item>
<title>Competing Risks in Clinical Trials: Do They Matter and How Should We Account for Them?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39232630/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240905041339&amp;v=2.18.0.post9+e462414
      <description>During patient follow-up in a randomized trial, some deaths may occur. Where death (or noncardiovascular death) is not part of an outcome of interest it is termed a competing risk. Conventional analyses (eg, Cox proportional hazards model) handle death similarly to other censored follow-up. Patients still alive are unrealistically assumed to be representative of those who died. The Fine and Gray model has been used to handle competing risks, but is often used inappropriately and can be...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 10;84(11):1025-1037. doi: 10.1016/j.jacc.2024.06.023.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">During patient follow-up in a randomized trial, some deaths may occur. Where death (or noncardiovascular death) is not part of an outcome of interest it is termed a competing risk. Conventional analyses (eg, Cox proportional hazards model) handle death similarly to other censored follow-up. Patients still alive are unrealistically assumed to be representative of those who died. The Fine and Gray model has been used to handle competing risks, but is often used inappropriately and can be misleading. We propose an alternative multiple imputation approach that plausibly accounts for the fact that patients who die tend also to be at high risk for the (unobserved) outcome of interest. This provides a logical framework for exploring the impact of a competing risk, recognizing that there is no unique solution. We illustrate these issues in 3 cardiovascular trials and in simulation studies. We conclude with practical recommendations for handling competing risks in future trials.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39232630/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240905041339&v=2.18.0.post9+e462414">39232630</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.023>10.1016/j.jacc.2024.06.023</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39232630</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>John Gregson</dc:creator>
<dc:creator>Stuart J Pocock</dc:creator>
<dc:creator>Stefan D Anker</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:creator>Milton Packer</dc:creator>
<dc:creator>Gregg W Stone</dc:creator>
<dc:creator>Cordula Zeller</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Competing Risks in Clinical Trials: Do They Matter and How Should We Account for Them?</dc:title>
<dc:identifier>pmid:39232630</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.023</dc:identifier>
</item>
<item>
<title>Pediatric Sedation Gets a Wake-Up Call</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39232629/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240905041339&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 10;84(11):1022-1024. doi: 10.1016/j.jacc.2024.06.034.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39232629/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240905041339&v=2.18.0.post9+e462414">39232629</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.034>10.1016/j.jacc.2024.06.034</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39232629</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>John N Kheir</dc:creator>
<dc:creator>Taylor M Smith</dc:creator>
<dc:creator>James A DiNardo</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Pediatric Sedation Gets a Wake-Up Call</dc:title>
<dc:identifier>pmid:39232629</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.034</dc:identifier>
</item>
<item>
<title>Association of Postnatal Opioid Exposure and 2-Year Neurodevelopmental Outcomes in Infants Undergoing Cardiac Surgery</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39232628/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240905041339&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Greater postnatal exposure to opioids was associated with worse neurodevelopmental outcomes across cognitive, language, and motor domains, independent of other less modifiable factors. This finding should motivate research and efforts to explore reduction in opioid exposure while preserving quality cardiac intensive care.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 10;84(11):1010-1021. doi: 10.1016/j.jacc.2024.06.033.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Opioids are commonly used to provide analgesia during and after congenital heart surgery. The effects of exposure to opioids on neurodevelopment in neonates and infants are not well understood.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to evaluate the associations between cumulative opioid exposure (measured in morphine mg equivalent) over the first year of life and 2-year neurodevelopmental outcomes (Bayley Scales of Infant and Toddler Development-Third/Fourth Edition [Bayley-III/IV] cognitive, language, and motor scores).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A single-center retrospective cohort study of infants undergoing congenital heart surgery was performed. Adjustment for measurable confounders was performed through multivariable linear regression.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 526 subjects were studied, of whom 32% underwent Society for Thoracic Surgeons-European Association for Cardio-Thoracic Surgery category 4 or 5 operations. In unadjusted analyses, higher total exposure to opioids was associated with worse scores across all 3 Bayley-III/IV domain scores (all P &lt; 0.05). After adjustment for measured confounders, greater opioid exposure was associated with lower Bayley-III/IV scores (cognitive: β = -1.0 per log-transformed morphine mg equivalents, P = 0.04; language: β = -1.2, P = 0.04; and motor: β = -1.1, P = 0.02). Total hospital length of stay, prematurity, genetic syndromes, and worse neighborhood socioeconomic status (represented either by Social Vulnerability Index or Childhood Opportunity Index) were all associated with worse Bayley-III/IV scores across all domains (all P &lt; 0.05).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Greater postnatal exposure to opioids was associated with worse neurodevelopmental outcomes across cognitive, language, and motor domains, independent of other less modifiable factors. This finding should motivate research and efforts to explore reduction in opioid exposure while preserving quality cardiac intensive care.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39232628/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240905041339&v=2.18.0.post9+e462414">39232628</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.033>10.1016/j.jacc.2024.06.033</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39232628</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Michael L O'Byrne</dc:creator>
<dc:creator>Keith Baxelbaum</dc:creator>
<dc:creator>Vicky Tam</dc:creator>
<dc:creator>Heather Griffis</dc:creator>
<dc:creator>Maryjane L Pennington</dc:creator>
<dc:creator>Alyssa Hagerty</dc:creator>
<dc:creator>Maryam Y Naim</dc:creator>
<dc:creator>Susan C Nicolson</dc:creator>
<dc:creator>Amanda J Shillingford</dc:creator>
<dc:creator>Tori N Sutherland</dc:creator>
<dc:creator>Lyla E Hampton</dc:creator>
<dc:creator>Nebiat G Gebregiorgis</dc:creator>
<dc:creator>Thuyvi Nguyen</dc:creator>
<dc:creator>Elizabeth Ramos</dc:creator>
<dc:creator>Joseph W Rossano</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Association of Postnatal Opioid Exposure and 2-Year Neurodevelopmental Outcomes in Infants Undergoing Cardiac Surgery</dc:title>
<dc:identifier>pmid:39232628</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.033</dc:identifier>
</item>
<item>
<title>Triglycerides and Cardiovascular Risk: Getting to the Heart of the Matter</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39232627/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240905041339&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 10;84(11):1007-1009. doi: 10.1016/j.jacc.2024.07.027.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39232627/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240905041339&v=2.18.0.post9+e462414">39232627</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.027>10.1016/j.jacc.2024.07.027</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39232627</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Peter P Toth</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Triglycerides and Cardiovascular Risk: Getting to the Heart of the Matter</dc:title>
<dc:identifier>pmid:39232627</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.027</dc:identifier>
</item>
<item>
<title>Sudden Hemodynamic Deterioration of a 75-Year-Old Woman With Progressive Jaw Pain</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39230916/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240905041339&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Sep 4. doi: 10.1001/jamacardio.2024.2695. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39230916/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240905041339&v=2.18.0.post9+e462414">39230916</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2695>10.1001/jamacardio.2024.2695</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39230916</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Sven L Van Laer</dc:creator>
<dc:creator>Pieterjan Van Rijckeghem</dc:creator>
<dc:creator>Vincent F M Segers</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Sudden Hemodynamic Deterioration of a 75-Year-Old Woman With Progressive Jaw Pain</dc:title>
<dc:identifier>pmid:39230916</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2695</dc:identifier>
</item>
<item>
<title>Addressing Evidence Gaps in Coronary Revascularization Trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39230898/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240905041339&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Sep 4. doi: 10.1001/jamacardio.2024.2778. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39230898/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240905041339&v=2.18.0.post9+e462414">39230898</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2778>10.1001/jamacardio.2024.2778</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39230898</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Gregg W Stone</dc:creator>
<dc:creator>Clyde W Yancy</dc:creator>
<dc:creator>Mario Gaudino</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Addressing Evidence Gaps in Coronary Revascularization Trials</dc:title>
<dc:identifier>pmid:39230898</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2778</dc:identifier>
</item>
<item>
<title>Genome-Wide Association Study of Accessory Atrioventricular Pathways</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39230897/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240905041339&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Associations were found between sequence variants and APs that were also associated with risk of PSVT, and thus likely atrioventricular reentrant tachycardia, but had allele-specific associations with AF and conduction disorders. Genetic variation in the modulation of heart rate, chronotropic response, and atrial or atrioventricular node conduction velocity may play a role in the risk of AP-affiliated arrhythmias. Further research into CCDC141 could provide insights...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Sep 4. doi: 10.1001/jamacardio.2024.2684. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Understanding of the genetics of accessory atrioventricular pathways (APs) and affiliated arrhythmias is limited.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To investigate the genetics of APs and affiliated arrhythmias.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was a genome-wide association study (GWAS) of APs, defined by International Classification of Diseases (ICD) codes and/or confirmed by electrophysiology (EP) study. Genome-wide significant AP variants were tested for association with AP-affiliated arrhythmias: paroxysmal supraventricular tachycardia (PSVT), atrial fibrillation (AF), ventricular tachycardia, and cardiac arrest. AP variants were also tested in data on other heart diseases and measures of cardiac physiology. Individuals with APs and control individuals from Iceland (deCODE Genetics), Denmark (Copenhagen Hospital Biobank, Danish Blood Donor Study, and SupraGen/the Danish General Suburban Population Study [GESUS]), the US (Intermountain Healthcare), and the United Kingdom (UK Biobank) were included. Time of phenotype data collection ranged from January 1983 to December 2022. Data were analyzed from August 2022 to January 2024.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURES: Sequence variants.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Genome-wide significant association of sequence variants with APs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The GWAS included 2310 individuals with APs (median [IQR] age, 43 [28-57] years; 1252 [54.2%] male and 1058 [45.8%] female) and 1 206 977 control individuals (median [IQR] year of birth, 1955 [1945-1970]; 632 888 [52.4%] female and 574 089 [47.6%] male). Of the individuals with APs, 909 had been confirmed in EP study. Three common missense variants were associated with APs, in the genes CCDC141 (p.Arg935Trp: adjusted odds ratio [aOR], 1.37; 95% CI, 1.24-1.52, and p.Ala141Val: aOR, 1.55; 95% CI 1.34-1.80) and SCN10A (p.Ala1073Val: OR, 1.22; 95% CI, 1.15-1.30). The 3 variants associated with PSVT and the SCN10A variant associated with AF, supporting an effect on AP-affiliated arrhythmias. All 3 AP risk alleles were associated with higher heart rate and shorter PR interval, and have reported associations with chronotropic response.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Associations were found between sequence variants and APs that were also associated with risk of PSVT, and thus likely atrioventricular reentrant tachycardia, but had allele-specific associations with AF and conduction disorders. Genetic variation in the modulation of heart rate, chronotropic response, and atrial or atrioventricular node conduction velocity may play a role in the risk of AP-affiliated arrhythmias. Further research into CCDC141 could provide insights for antiarrhythmic therapeutic targeting in the presence of an AP.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39230897/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240905041339&v=2.18.0.post9+e462414">39230897</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2684>10.1001/jamacardio.2024.2684</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39230897</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Hildur M Aegisdottir</dc:creator>
<dc:creator>Laura Andreasen</dc:creator>
<dc:creator>Rosa B Thorolfsdottir</dc:creator>
<dc:creator>Gardar Sveinbjornsson</dc:creator>
<dc:creator>Andrea B Jonsdottir</dc:creator>
<dc:creator>Lilja Stefansdottir</dc:creator>
<dc:creator>Gudmar Thorleifsson</dc:creator>
<dc:creator>Asgeir Sigurdsson</dc:creator>
<dc:creator>Gisli H Halldorsson</dc:creator>
<dc:creator>Julien Barc</dc:creator>
<dc:creator>Floriane Simonet</dc:creator>
<dc:creator>Vinicius Tragante</dc:creator>
<dc:creator>Asmundur Oddsson</dc:creator>
<dc:creator>Egil Ferkingstad</dc:creator>
<dc:creator>Jesper Hastrup Svendsen</dc:creator>
<dc:creator>Jonas Ghouse</dc:creator>
<dc:creator>Gustav Ahlberg</dc:creator>
<dc:creator>Christian Paludan-Müller</dc:creator>
<dc:creator>Katra Hadji-Turdeghal</dc:creator>
<dc:creator>Mariana Bustamante</dc:creator>
<dc:creator>Magnus O Ulfarsson</dc:creator>
<dc:creator>Anna Helgadottir</dc:creator>
<dc:creator>Solveig Gretarsdottir</dc:creator>
<dc:creator>Saedis Saevarsdottir</dc:creator>
<dc:creator>Ingileif Jonsdottir</dc:creator>
<dc:creator>Christian Erikstrup</dc:creator>
<dc:creator>Henrik Ullum</dc:creator>
<dc:creator>Erik Sørensen</dc:creator>
<dc:creator>Søren Brunak</dc:creator>
<dc:creator>Christian Jøns</dc:creator>
<dc:creator>Chaoqun Zheng</dc:creator>
<dc:creator>Connie R Bezzina</dc:creator>
<dc:creator>Kirk U Knowlton</dc:creator>
<dc:creator>Lincoln D Nadauld</dc:creator>
<dc:creator>Patrick Sulem</dc:creator>
<dc:creator>Sisse R Ostrowski</dc:creator>
<dc:creator>Ole B Pedersen</dc:creator>
<dc:creator>David O Arnar</dc:creator>
<dc:creator>Daniel F Gudbjartsson</dc:creator>
<dc:creator>Morten S Olesen</dc:creator>
<dc:creator>Henning Bundgaard</dc:creator>
<dc:creator>Hilma Holm</dc:creator>
<dc:creator>Kari Stefansson</dc:creator>
<dc:creator>DBDS consortium</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Genome-Wide Association Study of Accessory Atrioventricular Pathways</dc:title>
<dc:identifier>pmid:39230897</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2684</dc:identifier>
</item>
<item>
<title>Aficamten and Cardiopulmonary Exercise Test Performance: A Substudy of the SEQUOIA-HCM Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39230885/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240905041339&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: This prespecified analysis of the SEQUOIA-HCM randomized clinical trial found that aficamten treatment improved a broad range of exercise performance measures. These findings offer valuable insight into the therapeutic effects of aficamten.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Sep 4. doi: 10.1001/jamacardio.2024.2781. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Impaired exercise capacity is a cardinal manifestation of obstructive hypertrophic cardiomyopathy (HCM). The Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Obstructive HCM (SEQUOIA-HCM) is a pivotal study characterizing the treatment effect of aficamten, a next-in-class cardiac myosin inhibitor, on a comprehensive set of exercise performance and clinical measures.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To evaluate the effect of aficamten on exercise performance using cardiopulmonary exercise testing with a novel integrated measure of maximal and submaximal exercise performance and evaluate other exercise measures and clinical correlates.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was a prespecified analysis from SEQUOIA-HCM, a double-blind, placebo-controlled, randomized clinical trial. Patients were recruited from 101 sites in 14 countries (North America, Europe, Israel, and China). Individuals with symptomatic obstructive HCM with objective exertional intolerance (peak oxygen uptake [pVO2] ≤90% predicted) were included in the analysis. Data were analyzed from January to March 2024.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Randomized 1:1 to aficamten (5-20 mg daily) or matching placebo for 24 weeks.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary outcome was change from baseline to week 24 in integrated exercise performance, defined as the 2-component z score of pVO2 and ventilatory efficiency throughout exercise (minute ventilation [VE]/carbon dioxide output [VCO2] slope). Response rates for achieving clinically meaningful thresholds for change in pVO2 and correlations with clinical measures of treatment effect (health status, echocardiographic/cardiac biomarkers) were also assessed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 282 randomized patients (mean [SD] age, 59.1 [12.9] years; 115 female [40.8%], 167 male [59.2%]), 263 (93.3%) had core laboratory-validated exercise testing at baseline and week 24. Integrated composite exercise performance improved in the aficamten group (mean [SD] z score, 0.17 [0.51]) from baseline to week 24, whereas the placebo group deteriorated (mean [SD] z score, -0.19 [0.45]), yielding a placebo-corrected improvement of 0.35 (95% CI, 0.25-0.46; P &lt;.001). Further, aficamten treatment demonstrated significant improvements in total workload, circulatory power, exercise duration, heart rate reserve, peak heart rate, ventilatory efficiency, ventilatory power, and anaerobic threshold (all P &lt;.001). In the aficamten group, large improvements (≥3.0 mL/kg per minute) in pVO2 were more common than large reductions (32% and 2%, respectively) compared with placebo (16% and 11%, respectively). Improvements in both components of the primary outcome, pVO2 and VE/VCO2 slope throughout exercise, were significantly correlated with improvements in symptom burden and hemodynamics (all P &lt;.05).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: This prespecified analysis of the SEQUOIA-HCM randomized clinical trial found that aficamten treatment improved a broad range of exercise performance measures. These findings offer valuable insight into the therapeutic effects of aficamten.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05186818.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39230885/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240905041339&v=2.18.0.post9+e462414">39230885</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2781>10.1001/jamacardio.2024.2781</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39230885</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Matthew M Y Lee</dc:creator>
<dc:creator>Ahmad Masri</dc:creator>
<dc:creator>Michael E Nassif</dc:creator>
<dc:creator>Roberto Barriales-Villa</dc:creator>
<dc:creator>Theodore P Abraham</dc:creator>
<dc:creator>Brian L Claggett</dc:creator>
<dc:creator>Caroline J Coats</dc:creator>
<dc:creator>Juan Ramón Gimeno</dc:creator>
<dc:creator>Ian J Kulac</dc:creator>
<dc:creator>Isabela Landsteiner</dc:creator>
<dc:creator>Changsheng Ma</dc:creator>
<dc:creator>Martin S Maron</dc:creator>
<dc:creator>Iacopo Olivotto</dc:creator>
<dc:creator>Anjali T Owens</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:creator>Josef Veselka</dc:creator>
<dc:creator>Daniel L Jacoby</dc:creator>
<dc:creator>Stephen B Heitner</dc:creator>
<dc:creator>Stuart Kupfer</dc:creator>
<dc:creator>Fady I Malik</dc:creator>
<dc:creator>Lisa Meng</dc:creator>
<dc:creator>Amy Wohltman</dc:creator>
<dc:creator>Gregory D Lewis</dc:creator>
<dc:creator>SEQUOIA-HCM Investigators</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Aficamten and Cardiopulmonary Exercise Test Performance: A Substudy of the SEQUOIA-HCM Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:39230885</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2781</dc:identifier>
</item>
<item>
<title>Short-Term Effects of Lower Air Temperature and Cold Spells on Myocardial Infarction Hospitalizations in Sweden</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39230547/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240905041339&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This nationwide case-crossover study reveals that short-term exposures to lower air temperature and cold spells are associated with an increased risk of hospitalization for MI at lag 2 to 6 days.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 19:S0735-1097(24)07842-2. doi: 10.1016/j.jacc.2024.07.006. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Lower air temperature and cold spells have been associated with an increased risk of various diseases. However, the short-term effect of lower air temperature and cold spells on myocardial infarction (MI) remains incompletely understood.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purpose of this study was to investigate the short-term effects of lower air temperature and cold spells on the risk of hospitalization for MI in Sweden.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This population-based nationwide study included 120,380 MI cases admitted to hospitals in Sweden during the cold season (October to March) from 2005 to 2019. Daily mean air temperature (1 km<sup>2</sup> resolution) was estimated using machine learning, and percentiles of daily temperatures experienced by individuals in the same municipality were used as individual exposure indicators to account for potential geographic adaptation. Cold spells were defined as periods of at least 2 consecutive days with a daily mean temperature below the 10th percentile of the temperature distribution for each municipality. A time-stratified case-crossover design incorporating conditional logistic regression models with distributed lag nonlinear models using lag 0 to 1 (immediate) and 2 to 6 days (delayed) was used to evaluate the short-term effects of lower air temperature and cold spells on total MI, non-ST-segment elevation myocardial infarction (NSTEMI) and ST-segment elevation myocardial infarction (STEMI).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A decrease of 1-unit in percentile temperature at a lag of 2 to 6 days was significantly associated with increased risks of total MI, NSTEMI, and STEMI, with ORs of 1.099 (95% CI: 1.057-1.142), 1.110 (95% CI: 1.060-1.164), and 1.076 (95% CI: 1.004-1.153), respectively. Additionally, cold spells at a lag of 2 to 6 days were significantly associated with increased risks for total MI, NSTEMI, and STEMI, with ORs of 1.077 (95% CI: 1.037-1.120), 1.069 (95% CI: 1.020-1.119), and 1.095 (95% CI: 1.023-1.172), respectively. Conversely, lower air temperature and cold spells at a lag of 0 to 1 days were associated with decreased risks for MI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This nationwide case-crossover study reveals that short-term exposures to lower air temperature and cold spells are associated with an increased risk of hospitalization for MI at lag 2 to 6 days.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39230547/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240905041339&v=2.18.0.post9+e462414">39230547</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.006>10.1016/j.jacc.2024.07.006</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39230547</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Wenli Ni</dc:creator>
<dc:creator>Massimo Stafoggia</dc:creator>
<dc:creator>Siqi Zhang</dc:creator>
<dc:creator>Petter Ljungman</dc:creator>
<dc:creator>Susanne Breitner</dc:creator>
<dc:creator>Jeroen de Bont</dc:creator>
<dc:creator>Tomas Jernberg</dc:creator>
<dc:creator>Dan Atar</dc:creator>
<dc:creator>Stefan Agewall</dc:creator>
<dc:creator>Alexandra Schneider</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Short-Term Effects of Lower Air Temperature and Cold Spells on Myocardial Infarction Hospitalizations in Sweden</dc:title>
<dc:identifier>pmid:39230547</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.006</dc:identifier>
</item>
<item>
<title>Bridging Atrial and Ventricular Failure Through Biomarkers</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39230546/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240905041339&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 22:S0735-1097(24)08117-8. doi: 10.1016/j.jacc.2024.08.005. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39230546/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240905041339&v=2.18.0.post9+e462414">39230546</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.005>10.1016/j.jacc.2024.08.005</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39230546</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Alberto Aimo</dc:creator>
<dc:creator>Giorgia Panichella</dc:creator>
<dc:creator>Giuseppe Vergaro</dc:creator>
<dc:creator>Antoni Bayes-Genis</dc:creator>
<dc:creator>Michele Emdin</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Bridging Atrial and Ventricular Failure Through Biomarkers</dc:title>
<dc:identifier>pmid:39230546</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.005</dc:identifier>
</item>
<item>
<title>ApoA-I Infusions and Burden of Ischemic Events After Acute Myocardial Infarction: Insights From the AEGIS-II Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39230545/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240905041339&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In this prespecified exploratory analysis of the AEGIS-II trial, 4 weekly infusions of CSL112 among high-risk patients after AMI significantly reduced the total burden of nonfatal ischemic events and CV death at 180 and 365 days compared with placebo. (AEGIS-II [Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome]; NCT03473223).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 20:S0735-1097(24)08038-0. doi: 10.1016/j.jacc.2024.08.001. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Following an acute myocardial infarction (AMI), patients remain at risk for subsequent cardiovascular (CV) events. In the AEGIS-II trial, CSL112, a human apolipoprotein A-I derived from plasma that enhances cholesterol efflux, did not significantly reduce the first occurrence of CV death, myocardial infarction (MI), or stroke through 90 days compared with placebo. However, an analysis involving only the first event may not capture the totality of the clinical impact of an intervention because patients may experience multiple events.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This prespecified exploratory analysis examines the effect of CSL112 on total burden of nonfatal ischemic events (ie, recurrent MI and stroke) and CV death.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A total of 18,219 patients with AMI, multivessel coronary artery disease, and additional CV risk factors were randomized to either 4 weekly infusions of 6 g CSL112 (n = 9,112) or matching placebo (n = 9,107). A negative binomial regression model was applied to estimate the effect of CSL112 compared with placebo on the rate ratio (RR) of ischemic events.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: For CV death, MI, and stroke, there were numerically fewer total events at 90 days (503 vs 545 events; rate ratio [RR]: 0.88; 95% CI: 0.76-1.03, P = 0.11), and nominally significantly fewer total events at 180 days (745 vs 821 events, RR: 0.87; 95% CI: 0.77-0.99; P = 0.04) and 365 days (1,120 vs 1,211 events; RR 0.89; 95% CI: 0.80-0.99; P = 0.04). Subsequent events constituted 13% of events at 90 days, 17% at 180 days, and 22% at 1 year. Similar findings were seen with the total occurrence of nonfatal MI and CV death. When type II MIs, unlikely to be modified by enhancing cholesterol efflux, were excluded, there were nominally significant reductions in the total occurrence of nonfatal MI (excluding type 2) and CV death at all timepoints (90 days: RR: 0.81; 95% CI: 0.68-0.97; P = 0.02; 180 days: RR: 0.82; 95% CI: 0.71-0.95; P &lt; 0.01; 365 days: RR: 0.86; 95% CI: 0.76-0.98; P = 0.02).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In this prespecified exploratory analysis of the AEGIS-II trial, 4 weekly infusions of CSL112 among high-risk patients after AMI significantly reduced the total burden of nonfatal ischemic events and CV death at 180 and 365 days compared with placebo. (AEGIS-II [Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome]; NCT03473223).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39230545/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240905041339&v=2.18.0.post9+e462414">39230545</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.001>10.1016/j.jacc.2024.08.001</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39230545</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>C Michael Gibson</dc:creator>
<dc:creator>Gerald Chi</dc:creator>
<dc:creator>Danielle Duffy</dc:creator>
<dc:creator>M Cecilia Bahit</dc:creator>
<dc:creator>Harvey White</dc:creator>
<dc:creator>Serge Korjian</dc:creator>
<dc:creator>John H Alexander</dc:creator>
<dc:creator>A Michael Lincoff</dc:creator>
<dc:creator>Gaya Anschuetz</dc:creator>
<dc:creator>Ihab G Girgis</dc:creator>
<dc:creator>Jose C Nicolau</dc:creator>
<dc:creator>Renato D Lopes</dc:creator>
<dc:creator>Jan H Cornel</dc:creator>
<dc:creator>Kevin R Bainey</dc:creator>
<dc:creator>Peter Libby</dc:creator>
<dc:creator>Frank M Sacks</dc:creator>
<dc:creator>Paul M Ridker</dc:creator>
<dc:creator>Shaun G Goodman</dc:creator>
<dc:creator>Kenneth W Mahaffey</dc:creator>
<dc:creator>Stephen J Nicholls</dc:creator>
<dc:creator>Stuart J Pocock</dc:creator>
<dc:creator>Roxana Mehran</dc:creator>
<dc:creator>Robert A Harrington</dc:creator>
<dc:creator>AEGIS-II Committees and Investigators</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>ApoA-I Infusions and Burden of Ischemic Events After Acute Myocardial Infarction: Insights From the AEGIS-II Trial</dc:title>
<dc:identifier>pmid:39230545</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.001</dc:identifier>
</item>





























</channel>
</rss>